PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Hot topics

PlayLowering LDL-C: How low and for how long?

Lowering LDL-C: How low and for how long?

Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…

read more »
Posted on 11 November 2014 | Posted by Evan Stein | Posted in Hot topics, Videos
PlayLDL-C: how low should clinicians aim for?

LDL-C: how low should clinicians aim for?

Trials with monoclonal antibodies – PCSK9 inhibitors – will answer the question of how far should low density lipoprotein cholesterol (LDL-C) be reduced?

read more »
Posted on 11 November 2014 | Posted by Henry Ginsberg | Posted in Hot topics, Videos
IMPROVE-IT: will it prove anything?

IMPROVE-IT: will it prove anything?

Professor Anthony S. Wierzbicki, London UK Comments on the IMPROVE-IT debate Cardiovascular disease (CVD) guidelines are emphasising the use of clinical outcome data on major vascular events (American Heart Association/American College of Cardiology)1 or hard CVD events alone (UK NICE)2 . They have begun to…

read more »
Posted on 3 August 2014 | Posted by Anthony Wierzbicki | Posted in Hot topics, Article Archive

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
AstraZeneca

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.

LIB Therapeutics

Novartis

Sanofi

© Copyright 2026 PCSK9 Forum. All rights reserved